Crossmark

Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia

Crossref DOI link: https://doi.org/10.1038/s41551-025-01428-2

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Chao https://orcid.org/0000-0002-1023-1326
Wang, Huishu https://orcid.org/0009-0005-5966-1721
Liu, Lunan

Chen, Ruiqi

Mukherjee, Nandana

Tong, Jie

Kazmi, Shadab

Fang, Xiangyi

Witkowski, Matthew T.

Aifantis, Iannis

Ghassemi, Saba https://orcid.org/0000-0002-2415-3576
Chen, Weiqiang https://orcid.org/0000-0002-9469-8328
Funding

Funding for this research was provided by:

NSF | ENG/OAD | Division of Chemical, Bioengineering, Environmental, and Transport Systems (2103219)

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM133646)

Cancer Research Institute (CRI4018)

Leukemia and Lymphoma Society (6580-20)

American Society of Hematology

U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K22CA258520-01)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA252239)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA228135)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA242020)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (O1CA266212)

Cancer League of Colorado (222549)

Alex's Lemonade Stand Foundation for Childhood Cancer

St. Baldrick's Foundation

AABB | National Blood Foundation

United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-20-1-0417)
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 31 March 2023

Accepted: 12 May 2025

First Online: 1 July 2025

Competing interests

: I.A. is a consultant for Foresite Labs. M.T.W. has received royalties from the Walter and Eliza Hall Institute for the development of venetoclax unrelated to the current paper. C.M. and W.C. are inventors (New York University) on a patent (20240198337) for bone marrow on a chip technology and a patent (20230032623) for tumour-on-a-chip technology. The other authors declare no competing interests.

Document is current

Any future updates will be listed below